EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting mitochondrial impairment for the treatment of cardiovascular diseases: From hypertension to ischemia-reperfusion injury, searching for new pharmacological targets

Simona Todisco, Biagia Musio, Vito Pesce, Maria Maddalena Cavalluzzi, Giuseppe Petrosillo, Gianluigi La Piana, Maria Noemi Sgobba, Nikola Schlosserová, Lucas Cafferati Beltrame, Rosa Di Lorenzo, Vincenzo Tragni, Domenico Marzulli und 7 weitere

Biochemical Pharmacology · 2023

DOI: 10.1016/j.bcp.2022.115405 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2023. Verfasst von Simona Todisco und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Sciences, University of Basilicata, Viale dell'Ateneo Lucano, 10‑85100 Potenza, Italy. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Hypertension, Reperfusion Injury. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 473 Literaturangaben. Gefördert von: Ministero dell’Istruzione, dell’Università e della Ricerca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mitochondria and mitochondrial proteins represent a group of promising pharmacological target candidates in the search of new molecular targets and drugs to counteract the onset of hypertension and more in general cardiovascular diseases (CVDs). Indeed, several mitochondrial pathways result impaired in CVDs, showing ATP depletion and ROS production as common traits of cardiac tissue degeneration. Thus, targeting mitochondrial dysfunction in cardiomyocytes can represent a successful strategy to prevent heart failure. In this context, the identification of new pharmacological targets among mitochondrial proteins paves the way for the design of new selective drugs. Thanks to the advances in omics approaches, to a greater availability of mitochondrial crystallized protein structures and to the development of new computational approaches for protein 3D-modelling and drug design, it is now possible to investigate in detail impaired mitochondrial pathways in CVDs. Furthermore, it is possible to design new powerful drugs able to hit the selected pharmacological targets in a highly selective way to rescue mitochondrial dysfunction and prevent cardiac tissue degeneration. The role of mitochondrial dysfunction in the onset of CVDs appears increasingly evident, as reflected by the impairment of proteins involved in lipid peroxidation, mitochondrial dynamics, respiratory chain complexes, and membrane polarization maintenance in CVD patients. Conversely, little is known about proteins responsible for the cross-talk between mitochondria and cytoplasm in cardiomyocytes. Mitochondrial transporters of the SLC25A family, in particular, are responsible for the translocation of nucleotides (e.g., ATP), amino acids (e.g., aspartate, glutamate, ornithine), organic acids (e.g. malate and 2-oxoglutarate), and other cofactors (e.g., inorganic phosphate, NAD+, FAD, carnitine, CoA derivatives) between the mitochondrial and cytosolic compartments. Thus, mitochondrial transporters play a key role in the mitochondria-cytosol cross-talk by leading metabolic pathways such as the malate/aspartate shuttle, the carnitine shuttle, the ATP export from mitochondria, and the regulation of permeability transition pore opening. Since all these pathways are crucial for maintaining healthy cardiomyocytes, mitochondrial carriers emerge as an interesting class of new possible pharmacological targets for CVD treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesHypertensionReperfusion InjuryHumansMalatesAspartic AcidMitochondriaMitochondrial Membrane Transport ProteinsMitochondrial ProteinsAdenosine Triphosphate

Stichwörter der Autor:innen

AquaporinCardiolipinCardiovascular diseasesDrug-RepurposingGenomicsHypertensionIschemia reperfusion injuryMetabolomicsMitochondrial carriersMitochondrial diseasesMitochondrial dynamicsMitochondrial dysfunctionMitochondrial impairmentMitochondrial metabolite transport systemMitochondrial permeability transition pore

Substanzen

MalatesAspartic AcidMitochondrial Membrane Transport ProteinsMitochondrial ProteinsAdenosine Triphosphate

Autor:innen und Institutionen

  • Department of Sciences, University of Basilicata, Viale dell'Ateneo Lucano, 10‑85100 Potenza, Italy.
  • Polytechnic University of Bari, DICATECh, Via Orabona 4, 70125 Bari, Italy.
  • Department of Biosciences, Biotechnologies, Environment, University of Bari Aldo Moro, Via E. Orabona, 4, 70125 Bari, Italy.
  • Department of Pharmacy - Pharmaceutical Sciences, University of Bari Aldo Moro, Via E. Orabona 4, 70125 Bari, Italy.
  • Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies (IBIOM), National Research Council (CNR), 70126 Bari, Italy.
  • Department of Biosciences, Biotechnologies, Environment, University of Bari Aldo Moro, Via E. Orabona, 4, 70125 Bari, Italy; Department of Chemistry and Biochemistry, Mendel University in Brno, Zěmědelská 1, 61300 Brno,…

Förderung

  • Ministero dell’Istruzione, dell’Università e della Ricerca

Zitieren

APA

Todisco, S., Musio, B., Pesce, V., Cavalluzzi, M. M., Petrosillo, G., La Piana, G., Sgobba, M. N., Schlosserová, N., Cafferati Beltrame, L., Di Lorenzo, R., Tragni, V., Marzulli, D., Guerra, L., De Grassi, A., Gallo, V., Volpicella, M., Palese, L. L., Lentini, G., & Pierri, C. L. (2023). Targeting mitochondrial impairment for the treatment of cardiovascular diseases: From hypertension to ischemia-reperfusion injury, searching for new pharmacological targets. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2022.115405

Vancouver

Todisco S, Musio B, Pesce V, Cavalluzzi MM, Petrosillo G, La Piana G, et al. Targeting mitochondrial impairment for the treatment of cardiovascular diseases: From hypertension to ischemia-reperfusion injury, searching for new pharmacological targets. Biochemical Pharmacology. 2023. doi:10.1016/j.bcp.2022.115405

BibTeX
@article{Todisco2023,
  author = {Todisco, Simona and Musio, Biagia and Pesce, Vito and Cavalluzzi, Maria Maddalena and Petrosillo, Giuseppe and La Piana, Gianluigi and Sgobba, Maria Noemi and Schlosserová, Nikola and Cafferati Beltrame, Lucas and Di Lorenzo, Rosa and Tragni, Vincenzo and Marzulli, Domenico and Guerra, Lorenzo and De Grassi, Anna and Gallo, Vito and Volpicella, Mariateresa and Palese, Luigi Leonardo and Lentini, Giovanni and Pierri, Ciro Leonardo},
  title = {Targeting mitochondrial impairment for the treatment of cardiovascular diseases: From hypertension to ischemia-reperfusion injury, searching for new pharmacological targets},
  journal = {Biochemical Pharmacology},
  year = {2023},
  doi = {10.1016/j.bcp.2022.115405}
}
Kostenlos starten →